Boehringer Ingelheim study shows benefit of Pradaxa reversal agent Praxbind

Boehringer Ingelheim has announced new clinical trial data that demonstrates the effectiveness of its Pradaxa reversal agent Praxbind.

Final results from the RE-VERSE AD study showed that Praxbind was able to immediately and completely reverse the anticoagulant effect of Pradaxa in emergency situations, whether the patient required an urgent surgery or intervention, or if they had presented with uncontrollable or life-threatening bleeding.

The reversal of Pradaxa's effect allowed physicians to quickly initiate necessary emergency interventions and was observed in 100 percent of patients, with the effects becoming evident immediately and maintained for 24 hours in most patients.

Praxbind is the first and only approved specific reversal agent for a non-vitamin K antagonist oral anticoagulant currently available.

Professor Jorg Kreuzer, vice-president for cardiovascular medicine at Boehringer Ingelheim, said: "The good news for patients and physicians is that Praxbind is already approved in 61 countries and is available in more than 8,200 sites worldwide, where it can be used to treat patients when urgently needed."

The company is also studying Praxbind in the RE-VECTO programme, which evaluates usage patterns in a clinical practice setting. Results from these studies are expected at the end of 2018.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.